Sign in

You're signed outSign in or to get full access.

Joe Diaz

Research Analyst at Lytham Partners

Joe Diaz is Managing Partner at Lytham Partners, specializing in advising corporate management teams on operational and valuation strategies with a primary focus on enhancing shareholder value. Over more than 25 years, he has led strategic investor relations programs for companies such as AdvancePCS (now Caremark Rx, Inc.), Allied Waste, Bio-Rad Laboratories, CNS, Inc., Abaxis, and others, resulting in significant capital appreciation for his clients. Diaz started his career in portfolio management, previously working at a leading regional investment banking and securities firm where he operated Arizona’s first United Mexican States Federal Treasury Certificate (CETES) desk before joining Lytham Partners. He holds a B.A. from Arizona State University and is recognized for his depth of industry knowledge and effectiveness in investor communications, but there is no publicly listed evidence of FINRA registration or securities licenses.

Joe Diaz's questions to IMMUCELL CORP /DE/ (ICCC) leadership

Question · Q3 2025

Joe Diaz, acting as moderator, inquired about the primary factors contributing to ImmuCell's significant gross margin improvement observed during the third quarter of 2025.

Answer

Timothy Fiori, CFO of ImmuCell Corporation, attributed the gross margin improvement primarily to enhanced manufacturing performance, a composite price increase of approximately 6% implemented in 2025, and the positive impact of increased sales volume leading to better economies of scale.

Ask follow-up questions

Fintool

Fintool can predict IMMUCELL CORP /DE/ logo ICCC's earnings beat/miss a week before the call